Area of research
Immunology · Oncology
Research interest
Research focused on Cytotoxic T cell and Chimeric antigen receptor, with related work in Lymphoma, Lymphoblast, Interleukin 21. Notable publications include 'Treatment of patients with advanced cancer with the natural killer cell line NK-92', 'Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor', and 'CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies'.
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
<scp>CD</scp>19‐<scp>CAR</scp> engineered <scp>NK</scp>‐92 cells are sufficient to overcome <scp>NK</scp> cell resistance in B‐cell malignancies
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Treatment of patients with advanced cancer with the natural killer cell line NK-92